Sponsored satellite symposia

Daiichi Sankyo/AstraZeneca sponsored satellite symposium
A team approach to the treatment of patients with HER2-postive metastatic breast cancer

On-demand session (duration: 01h15):
Welcome and meeting objectives Véronique Diéras, FR
A patient in your clinical practice Véronique Diéras, FR
My patient with HER2-positive metastatic breast cancer: What are my current treatment options? Rupert Bartsch, AT
Adverse event awareness and management: Optimising patient outcomes Andreas Charalambous, CY
My patient with HER2-positive metastatic breast cancer: What possibilities might there be in the future? Véronique Diéras, FR
Panel discussion Véronique Diéras, FR and Rupert Bartsch, AT and Andreas Charalambous, CY
Live Q&A: Friday 5 November 2021 17:30-17:45
Véronique Diéras, FR - Rupert Bartsch, AT - Andreas Charalambous, CY
Symposium faculty Rupert Bartsch, Medical University Vienna, Vienna, AT Andreas Charalambous, Cyprus University of Technology, Cyprus, CY Véronique Diéras, Centre Eugène Marquis, Rennes, FR

Lilly sponsored satellite symposium
Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. Real world discussion

On-demand session (duration: 01h00):
Welcome and introduction Miguel Martin, ES
Clinical case discussion: high risk ER+/HER2- early breast cancer Presenter: Elisabetta Munzone, IT Experts panel: Isabel Rubio, ES - Philip Poortmans, BE - Nicola Fusco, IT Chair: Miguel Martin, ES
Clinical case discussion: de novo metastatic disease Presenter: Carmen Criscitiello, IT Experts panel: Isabel Rubio, ES - Philip Poortmans, BE - Nicola Fusco, IT Chair: Miguel Martin, ES
Take home messages Miguel Martin, ES
Symposium faculty Carmen Criscitiello, IRCCS European Institute of Oncology (IEO), Milan, IT Nicola Fusco, University of Milan, IRCCS European Institute of Oncology (IEO), Milan, IT Miguel Martin, Hospital Universitario Gregorio Marañon, Madrid, ES Elisabetta Munzone, IRCCS European Institute of Oncology (IEO), Milan, IT Philip Poortmans, University of Antwerp, Wilrijk-Antwerp, BE Isabel Rubio, Navarra University Clinic, Madrid, ES

Novartis sponsored satellite symposium
What matters to patients with HR+ HER2– ABC: Expanding options for living better for longer

On-demand session (duration: 01h30):
Opening remarks Michelino De Laurentiis, IT
CDK4/6 inhibitors in HR+ HER2– ABC: Maximizing impact on overall survival and quality of life Michelino De Laurentiis, IT - Victoria Harmer, UK
Discussion Michelino De Laurentiis, IT - Christian Singer, AT - Victoria Harmer, UK
Personalizing treatment to ensure optimal benefit from PI3K inhibitors in HR+ HER2– ABC Christian Singer, AT - Victoria Harmer, UK
Discussion Michelino De Laurentiis, IT - Christian Singer, AT - Victoria Harmer, UK
Closing remarks Michelino De Laurentiis, IT
Symposium faculty Michelino De Laurentiis, National Cancer Institute “Fondazione Pascale”, Naples, IT Christian Singer, Medical University of Vienna, Vienna, AT Victoria Harmer, Imperial College Healthcare NHS Trust, London, UK

Pfizer sponsored satellite symposium
Raising awareness of underserved patient populations: Solutions from the real world

On-demand session (duration: 45min):
Welcome and introduction to underserved populations Joanna Taylor, UK
Managing underserved patients in the real-world Eduard Vrdoljak, HR - Etienne Brain, FR
Q&A and faculty discussion Etienne Brain, FR - Joanna Taylor, UK - Eduard Vrdoljak, HR
Symposium faculty Etienne Brain, René-Huguenin Hospital – Insitut Curie, Saint-Cloud, FR Joanna Taylor, After Breast Cancer Diagnosis, Oldham, UK Eduard Vrdoljak, University of Split and KGB Split, Split, HR

Live Q&A: Saturday 6 November 2021 13:30-13:45:
Etienne Brain, FR - Joanna Taylor, UK - Eduard Vrdoljak, HR

Seagen sponsored satellite symposium
Multidisciplinary team perspectives on the evolving treatment landscape in HER2+ MBC

On-demand session (duration: 45 min):
Introduction to the session - Filippo Montemurro, IT (Chair)
Welcoming our patient: What are the considerations for her management?
The disease of our patient progresses: How could emerging treatment options support her journey?
Our patient experiences brain metastases: What are her options?
Icro Meattini, IT - Filippo Montemurro, IT - Doris Schmitt, DE
Live Q&A: Friday 5 November 2021 13:30-13:45
Icro Meattini, IT - Filippo Montemurro, IT - Doris Schmitt, DE
Symposium faculty Icro Meattini, University of Florence, Florence, IT Filippo Montemurro, Fondazione del Piemonte per l’Oncologia/Candiolo Cancer Institute Candiolo, IT Doris Schmitt, Patient representative, DE